---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-25-000003"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:52:59.732960+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exagen gets conditional NY approval for new SLE/RA biomarkers; reports record 2024 revenue of $55.3-55.8M

## Summary
- Conditional NY State approval for new SLE and RA biomarker assays on AVISE CTD; commercial launch January 2025.
- Preliminary FY2024 revenue $55.3-$55.8M (record), net loss $14.8-$15.8M, adjusted EBITDA ($9.8)-($10.8M).
- AVISE CTD trailing 12-mo ASP $408-$412, up $72-$76 vs Q4 2023; net neutral cash usage in Q4.
- Cash, cash equivalents and restricted cash $22.2M as of Dec 31, 2024.
- CEO says profitability 'firmly within reach' with strong growth catalysts entering 2025.

## SEC filing metadata
- accession: 0001274737-25-000003
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473725000003/0001274737-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473725000003/exdx-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-25-000003
- JSON: https://secwatch.observer/filing/0001274737-25-000003.json
- Plain text: https://secwatch.observer/filing/0001274737-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.